Clinical Trial Update: Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study [Phase 2]

View source ↗

Summary

This ClinicalTrials.gov update describes a Phase 2, single-arm study evaluating neoadjuvant and adjuvant toripalimab plus cetuximab in locally recurrent, resect…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Cetuximab (cetuximab)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Conditions: Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING